Relief of Postherpetic Neuralgia with Transforaminal Epidural Injection of Magnesium -A Case Report- by Yu, Ho Kyoung et al.
Korean J Pain 2011 March; Vol. 24, No. 1: 53-56
pISSN 2005-9159  eISSN 2093-0569
DOI：10.3344/kjp.2011.24.1.53
|C a s e  R e p o r t|
Relief  of  Postherpetic  Neuralgia  with  Transforaminal 
Epidural  Injection  of  Magnesium
-A Case Report-
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Although postherpetic neuralgia (PHN) is a common chronic pain syndrome, the pathophysiology of this 
disorder is not well known and management is often very difficult. N-methyl-D-Aspartate (NMDA) receptor 
antagonists are known to be effective in PHN, and magnesium, a physiological blocker of NMDA receptors, 
is widely used to treat various chronic pain disorders. Here, we present a case of the PHN refractory to 
conventional treatment, which was treated successfully with transforaminal epidural injection of magnesium 
sulphate at the affected dermatome. (Korean  J  Pain  2011;  24:  53-56)
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    Postherpetic neuralgia (PHN) is a chronic neuropathic 
pain syndrome that occurs after reactivation of varicella 
zoster virus infection with damage to sensory ganglia in 
nerve roots [1]. Numerous treatment strategies for PHN, 
including topical lidocaine patches, antidepressants, anti-
convulsants,  corticosteroids,  opioids  and  nerve  blocks, 
have shown some degree of efficacy [2], but the effects 
are often limited and many patients are refractory to these 
treatments. Previous report has suggested that N-meth-
yl-D-Aspartate  (NMDA)  receptor  antagonists,  such  as 
ketamine can decrease pain associated with PHN. However, 
adverse  effects  such  as  psychomimetic  effects  limit  its 
therapeutic use, even at low doses [3]. 
    Magnesium, which is also a NMD A receptor antago-
nist, has been used in the treatment of neuropathic pain 
usually via the intravenous route and is free of psychomi-
metic side effects. However, the anti-nociceptive effect of 
intravenous magnesium remains controversial [4], and in-
creases in serum magnesium concentration during and after 
administration may cause serious, sometimes fatal compli-
cations  such  as  respiratory  paralysis,  hypothermia  and 
coma. The epidural route of administration, especially the 
t r a n s f o r a m i n a l  e p i d u r a l  r o u t e ,  h a s  a d v a n t a g e s  i n  t a r -
get-specific delivery of drugs and reduction in the dose of 54 Korean J Pain Vol. 24, No. 1, 2011
Fig. 1. Posterior-anterior fluoroscopic image shows 
spreading of contrast media in left T3 nerve root and 
epidural space.
medications used. Therefore, epidural administration is su-
perior to systemic injection if the efficacy can be guaran-
teed.
    Here, we present a patient with PHN refractory to 
c o n v e n t i o n a l  t h e r a p y  t r e a t e d  s u c c e s s f u l l y  b y  t r a n s f o r a-
minal epidural magnesium injection (TFEMI).
CASE  REPORT
    A 60-year-old woman (height, 162 cm; weight, 61 kg) 
visited pain clinic with tactile allodynia and electric shock- 
like pain in the left dorsal scapular area around the T3 
d erm ato m e, w hi c h h a d bee n d ia gn osed  as P HN a bo u t 1 
month previously and attack of the herpes zoster was 1 
year ago. The 100-mm visual analogue scale (VAS) of allo-
dynia and electric shock-like pain was rated between 70 
and 80 mm on a scale from 0 (no pain) to 100 (worst pain 
imaginable). The interlaminar epidural block was performed 
at the T3-4 space by the paramedian approach with 5 ml 
of 0.2% ropivacaine and 20 mg of triamcinolone acetate. 
Pregabalin and morphine at doses of 150 mg and 10 mg, 
respectively, twice a day, amitriptyline at a dose of 10 mg 
before sleep and topical lidocaine patches were prescribed. 
Dosages of all drugs were adjusted depending on the side 
effects during the follow-up period. Epidural blocks were 
repeated twice with a 1-week interval and the continuous 
intravenous infusion of ketamine (60 mg) was performed 
o v e r  a  p e r i o d  o f  1  h o u r  t w i c e  a  w e e k  u n d e r  c a r e f u l  
monitoring. The dose of ketamine was increased gradually 
up to 120 mg. After 1 month elapsed, electric shock-like 
pain was reduced to a VAS score of 30/100, but allodynia 
was not diminished (VAS score of 70/100).
    After 4 months elapsed, we decided to administer 
magnesium sulfate via the intravenous route. And it was 
done with continuous intravenous infusion of 1,000 mg of 
magnesium sulfate in 50 ml of normal saline for 1 hour. 
B e f o r e  a n d  a f t e r  i n f u s i o n ,  t h e  s e r u m  m a g n e s i u m  l e v e l s 
w e r e  c h e c k e d .  A f t e r  m a g n e s i u m  t h e r a p y ,  s h e  f e l t  v e r y 
good about her pain and the VAS of allodynia was reduced 
to 40-50. At 1-week follow-up, she was very satisfied 
with the treatment and reported the reduction of allodynia 
on the dorsal scapular area of up to 50% (VAS 25-30/100). 
However, the serum magnesium level had increased above 
n o r m a l  r a n g e  ( 2 . 3  m E q / L  t o  2 . 9  m E q / L )  a f t e r  i n f u s i o n . 
Although it was below the serum level reveals of the ad-
v erse eff ect, we decided to stop in tra v enous infusion of 
magnesium sulfate. For more accurate and safe delivery 
of magnesium to the target site, we applied magnesium 
using the transforaminal epidural injection technique. 
    With the patient’s informed consent, left T3 TFEMI 
was performed  under fluoroscopy guidance. The  patient 
was placed in the prone position and draped in the sterile 
manner. A 22-gauge, 3.5-inch spinal needle was advanced 
in t o  t h e l e ft .  T 3  n e r v e r oo t  f o r a m e n u n d e r  fl u o r os c o p i c 
guidance. The final needle placement was confirmed on 
posterior-anterior  and  lateral  fluoroscopic  images. 
Identification  of  the  T3  nerve  root  sheath  and  epidural 
space was performed using contrast media (Fig. 1). Then, 
100 mg of magnesium sulphate and 1 ml of 0.2% ropiva-
caine (total volume, 2 ml) was carefully injected. TFEMI 
was repeated twice with a 1-week interval (total of three 
times) and the degree of pain decreased gradually during 
the follow-up period.
    One week after the last procedure, the V AS score of 
allodynia decreased to 15/100 and all medications except 
pregabalin  were  discontinued.  The  VAS  was  10/100 
thr o ugh ou t 1-m on th f o llo w-u p, and pr ega ba lin ha d a lso 
been tapered. The patient remained free of symptoms at 
6-month follow-up.
DISCUSSION
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about the magnesium administration by the transforaminal 
epidural route in patients with neuropathic pain. Here, in 
our report of PHN patient, this treatment resulted in effec-
tive pain relief.
    Previous studies have demonstrated the anti-allodynic 
effects of NMDA receptor antagonists in neuropathic pain 
disorders [3,5]. Among the currently available NMDA re-
ceptor antagonists, ketamine is the most widely used one 
for the treatment of neuropathic pain. However, ketamine 
is not always effective and psychomimetic side effects are 
frequent.
    Magnesium can antagonize NMD A receptor channels 
by  blocking  calcium  influx  in  a  voltage-gated  manner. 
Intravenous administration of magnesium is efficacious in 
the  management  of  various  conditions  associated  with 
neuropathic pain, including PHN [6,7]. Demirkaya and col-
l e a g u e s  r e v e a l e d  1  g  i . v .  M g  s u l f a t e  i s  e f f e c t i v e  i n  t h e 
treatment  of  migraine  attacks  [8]  and  Collins  and  col-
leagues reported that 70 mg/kg magnesium sulphate in-
fusions in 4 hours for 5 days reduced pain in patients with 
complex regional pain syndrome [9]. Whether intravenous 
administration of magnesium can achieve a sufficient con-
centration in the cerebrospinal fluid to block NMDA re-
ceptors is unclear [4,10] and studies have reported on the 
limited efficacy of magnesium when administered via the 
intravenous route [11,12]. Furthermore, even if the dose of 
intravenously administered magnesium is not sufficient to 
present toxicity, patients are still at risk of magnesium 
overdose.
    Neuraxial administration of magnesium is an “off- 
label” use, and the safety of this technique in human sub-
jects is still undetermined. However, animal studies [13,14] 
showed  that  intrathecally  administered  magnesium  was 
free  of  neurotoxicity,  and  recent  studies  have  demon-
strated  the  safety  of  magnesium  administration  via  the 
epidural [15,16] or intrathecal [14,17] route in humans. Our 
patient showed no neurological deficit during the follow-up 
period.
    In fact, the exact site of action of epidurally admini-
stered  magnesium  (i.e.,  spinal  or  supraspinal)  remains 
unclear. However, comparison with previous reports re-
garding intravenous magnesium administration suggested 
that the low dose epidural magnesium used in our patient 
was unlikely to result in systemic effects.
    In conclusion, TFEMI showed a f avourable result in the 
t r e a t m e n t  o f  i n t r a c t a b l e  a l l o d y n i a  a s s o c i a t e d  w i t h  P H N . 
This study was performed in only a single case, and further 
i n v e s t i g a t i o n s  a r e  r e q u i r e d  t o  d e t e r m i n e  t h e  e f f i c a c y  o f 
TFEMI in th e m ana gemen t of a ll od ynia in patien ts with 
PHN.
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